References
- Haustein R, de Millas C, Hoër A et al. Saving money in the European healthcare systems with biosimilars. Generics Biosimilars Initiat J 2012;1:120-6
- What you need to know about biosimilar medicinal products: process on corporate responsibility in the field of pharmaceuticals access to medicines in Europe. European Commission. Consensus Information Paper, 2013. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_report_en.pdf
- Grabowski HG, Ridley DB, Schulman KA. Entry and competition in generic biologicals. Manag Decis Econ 2007;28:439-51
- Schellekens H. How similar ‘biosimilars’ need to be? Nat Biotechnol 2004;22:1357-9
- Simoens S. Health economics of market access for biopharmaceuticals and biosimilars. J Med Econ 2009;12:211-18
- Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape. IMS Health Whitepaper, 2011. http://www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars_Whitepaper.pdf. Accessed 2015 April 27
- FDA News Release - FDA approves first biosimilar product Zarxio, March 6, 2015. U.S. Food and Drug Administration, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm. Accessed 2015 April 12
- Bocquet F, Paubel P, Fusier I et al. Biosimilar Granulocyte-Stimulating factor uptakes in the EU-5 Markets: a descriptive analysis. Appl Health Econ Health Policy 2014;12:315-26
- Grabowski H, Guha R, Salgado M. Biosimilar competition: lessons from Europe. Nat Rev 2014;13:99-100s
- Bocquet F, Paubel P, Fusier I et al. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience. Appl Health Econ Health Policy 2015;13:47-59
- Glaeske G, Schicktanz C, Barmer GEK. Arzneimittel report 2011 Bremen: Universität Bremen. Abteilung für Gesundheitsökonomie, Gesundheitspolitik und Versorgungs-forschung, 2011. http://www.zes.uni-bremen.de/uploads/News/2011/110713_Kurzfassung.pdf Accessed 2015 April 10